Fibrillation data bode well for DU-176b as it moves to Phase III
This article was originally published in Scrip
Daiichi Sankyo's oral direct Factor Xa inhibitor DU-176b has moved into a pivotal Phase III study in atrial fibrillation (AF) patients after demonstrating safety comparable to warfarin at once-daily doses in a new Phase II trial.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.